AU659422B2 - Composition containing antihistamine H2 receptor antagonists and bioadhesive material - Google Patents

Composition containing antihistamine H2 receptor antagonists and bioadhesive material

Info

Publication number
AU659422B2
AU659422B2 AU89098/91A AU8909891A AU659422B2 AU 659422 B2 AU659422 B2 AU 659422B2 AU 89098/91 A AU89098/91 A AU 89098/91A AU 8909891 A AU8909891 A AU 8909891A AU 659422 B2 AU659422 B2 AU 659422B2
Authority
AU
Australia
Prior art keywords
histamine
receptor antagonist
treatment
cimetidine
gastric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU89098/91A
Other versions
AU8909891A (en
Inventor
Mark Coke
Adrian Francis Davis
John Edward O'mullane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of AU8909891A publication Critical patent/AU8909891A/en
Application granted granted Critical
Publication of AU659422B2 publication Critical patent/AU659422B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Description

Composition containing antihistamine H2 receptor antagonists and bioadhesive material.
This invention relates to the treatment of gastric disorders and pharmaceutical compositions for use therein. More
particularly the invention relates to the local treatment of gastric disorders, especially acute gastric disorders such as acid indigestion, heartburn and gastritis, and gastric and peptic ulcer, using orally administrable pharmaceutical compositions comprising a histamine H2-receptor antagonist contained within a drug delivery system. Compositions for use in the invention are specifically adapted to provide local delivery across the stomach wall to the H2-receptor on the parietal cell receptor. Histamine H2-receptor antagonists, for example cimetidine, ranitidine, nizetidine and famotidine, reduce acid secretion by acting directly on the acid-secreting parietal cell
located within the gastric gland of the stomach wall. Although histamine H2-receptor antagonists are remarkably effective in the treatment of many gastric disorders, in particular peptic and gastric ulcers, there exist certain patient groups which do not respond to treatment. In
addition, the time lapse between dosing and onset of action, limits the potential benefit of histamine H2-receptor
antagonists in the treatment of acute, self-limiting gastric disorders.
A significant proportion of gastric and peptic ulcer
patients, referred to as non-responders, do not respond to conventional histamine H2-receptor antagonist therapy.
(Walker et al.: Frequent non-response to histamine
H2-receptor antagonists in cirrhotics; Gut, 30, 1105-9,
1989; and Brack A. et al.: Clinical failures with
cimetidine; Surgery, 88(3), 417-24. In addition, the known poor response to histamine
H2-receptor antagonist treatment by hypersecreting patients, for example critically ill, multiple trauma patients (Martin L. et al. : Failure of cimetidine prophylaxis in the
critically ill; Arch. Surg., 114, 492-6, 1979) or those with Zollinger-Ellison syndrome (Stabile B.G. et al.: Failure of histamine H2-receptor antagonist therapy in
Zollinger-Ellison syndrome; Am. J. Surg., 145, 17-23, 1983) has led to the development of alternative treatments, notably the use of proton-pump inhibitors.
Histamine H2-receptor antagonists are of potential benefit in the self-medication of acute, self-limiting gastric disorders such as hyperacidity. However, their slow onset of action is unlikely to meet the consumer requirement for rapid relief of symptoms.
Moreover, it will be appreciated that use of high dose levels in an attempt to achieve rapid relief of symptoms is not appropriate for non-prescription use. Indeed, a
reduction from the standard therapeutic dose would be desirable for self-medication. Co-administration of histamine H2-receptor antagonists and other pharmaceutically active materials, including
sucralfate and other antacids, has been investigated. The rationale for co-administration with antacid is that the antacid brings about rapid relief from the symptoms of excess stomach acidity by neutralisation whereas the
histamine H2-receptor antagonist acts independently by inhibiting secretion of acid from the parietal cell.
However, it is well known (Bodemar G. et al., Lancet, 1, 444-445, 1979; Mihaly G.W. et al., B.M.J., 285, 998-9, 1982; Lin. J.H. et al., B.J. Clin. Pharmacol. 24, 551-3, 1987) that when histamine H2-receptor antagonists are co-administered with antacids, especially antacids with high acid-neutralising capacity, a substantial reduction in the plasma bioavailability of the histamine H2-receptor
antagonist is frequently observed. Histamine H2-receptor antagonist - antacid combinations are therefore generally contraindicated.
Bioadhesive materials have received considerable attention as platforms for controlled drug delivery. They can be targetted to specific drug administration sites, prolong the residence time and ensure an optimal contact with the absorbing surface. Many different types of bioadhesive materials, both natural and synthetic, can be used in the design of controlled drug delivery systems.
Sucralfate is a basic aluminium sulphate sucrose complex having ulcer healing and buffering properties. According to the literature, sucralfate has been shown to act by forming a bioadhesive gel structure which is believed to provide a local protective barrier. It has been reported that
sucralfate does not interfere with the absorption of
histamine H2-receptor antagonists. Clinical studies have indicated a combination therapy to be of potential benefit.
EP-A-O 286 781 (Heumann Pharma) relates to pharmaceutical preparations with cytoprotective effect on the
gastrointestinal tract containing a combination of a
histamine H2-receptor antagonist and an antacid substance which is able to give functional cytoprotection. Sucralfate is identified as an example of the antacid substance. It is described as giving functional cytoprotection but having a comparatively low acid-netutralising effect. EP-A-O 403 048 (Warner-Lambert), published on December 19, 1990, describes medicated compositions comprising sucralfate and a therapeutically effective amount of a medicament which is a) substantially water insoluble, or b) a mixture of a water-soluble medicament and a release-delaying material which on admixture forms a substantially water-insoluble medicament. In a preferred embodiment, the medicament is selected from the group consisting of inter alia antacids and anti-ulcer medicaments. Compositions comprising
sucralfate plus antacid and sucralfate plus an anti-ulcer medicament are described as cytoprotective compositions, useful in the treatment of peptic ulcers by forming an ulcer-adherent protective gel barrier. EP-A-O 193 400 (Reckitt and Colman) describes pharmaceutical compositions comprising mixtures of a histamine H2-receptor antagonist and sodium polyacrylate in the weight ratio 10 : 1 to 1 : 10. The compositions are described for use in the treatment of gastritis or of gastro-duodenal ulcers. The compositions may include an antacid. Use of antacid is described as resulting in a reduction in the viscosity of the liquid compositions, thereby providing some degree of viscosity control in the design of readily pourable liquid preparations.
US 4,615,697 (Robinson) discloses a controlled release composition comprising an effective amount of a treating agent, which may be a medicament, and a bioadhesive material which is a water-swellable and water-insoluble, fibrous, cross-linked carboxy-functional polymer. The controlled release compositions are described as adhering to the skin or to mucous membranes in the presence of water. Cimetidine is listed as an example of a medicament. Current treatments using histamine H2-receptor antagonists act systemically, i.e. the histamine H2-receptor antagonist is delivered to the parietal cell receptor from the blood.
International Patent Application No. PCT/GB91/00953
describes oral treatment of gastric disorders using a histamine H2-receptor antagonist in combination with an antacid to promote local delivery of the histamine H2-receptor antagonist to the receptor of the parietal cell wall. The increase in stomach wall receptor site
bioavailability of the histamine H2-receptor antagonist increases the capacity of the histamine H2-receptor
antagonist to reduce acid secretion compared with that of histamine H2-receptor antagonist alone.
The increase in acid-secretion reducing capacity is
described as being advantageous in the treatment of ulcer patients, in particular hypersecreting patients, in the treatment of those patients diagnosed as non-responders, and also to reduce the onset-phase of single-dose, self-medication for acute gastric disorders, for example gastric orders due to hyperacidity.
It has now been found that an intimate mixture comprising a histamine H2-receptor antagonist with a bioadhesive
material, for example sucralfate, buffered at or around the pKa of the histamine H2-receptor antagonist, provides an effective therapy for gastric disorders, mediated through local delivery of the histamine H2-receptor antagonist directly into the parietal cell receptor of the stomach wall.
Accordingly, the present invention provides the use of an orally administrable pharmaceutical composition comprising a histamine H2-receptor antagonist and a bioadhesive material, for the manufacture of a medicament for the treatment of gastric disorders, characterised in that the composition is formulated as an intimate mixture whereby the bioadhesive material and the histamine H2-receptor antagonist form, in situ, a bioadhesive complex, locally targeting the histamine H2-receptor antagonist to the stomach wall; and the
composition is optimally buffered to confer a pH
substantially equal to that of the pKa of the histamine H2-receptor antagonist.
The invention also provides a method of treatment of gastric disorders comprising administering to a sufferer an
effective amount of a locally acting pharmaceutical
composition comprising an intimate mixture of a histamine H2-receptor antagonist and a bioadhesive material forming in situ a bioadhesive complex; and a buffering component to confer a pH substantially equal to that of the pKa of the histamine H2-receptor antagonist.
In a further aspect, the invention provides a locally acting pharmaceutical composition for use in the treatment of gastric disorders which comprises an intimate mixture of a histamine H2-receptor antagonist and a bioadhesive material, and a buffering component to confer a pH substantially equal to that of the pKa of the histamine H2-receptor antagonist.
Bioadhesive materials for use in compositions of the present invention include materials, both natural and synthetic, which are capable of adhering to biological surfaces such as mucus membranes. Examples of bioadhesive materials include natural gums and plant extracts and synthetic materials such as sucralfate, cellulose derivatives, acrylic acid and methacrylic acid derivatives, for example cross-linked acrylic and methacrylic acid copolymers available under the Trade Names CARBOPOL and POLYCARBOPHIL .
Compositions for use in the invention are optimally buffered by the use of a buffering component which is suitably an antacid having equilibrium pH, acid neutralising capacity and gastric residence time values which provide a pH profile with time conferring a local pH level substantially equal to that of the pKa of the histamine H2-receptor antagonist. It will be appreciated that when the bioadhesive material is sucralfate which has buffering properties, it may function as the buffering component of the pharmaceutical
composition. This approach of locally delivering H2-receptor antagonists via the stomach mucosa is of particular benefit in the self-medication of acute, self-limiting gastric disorders such as hyperacidity. It is understood that H2-RA therapy fails in Zollinger-Ellison syndrome due to low levels of the drug at the H2-receptor of the parietal cells. Local delivery according to the invention which increases the concentration of drug at the H2-receptors of the parietal cell and renders the histamine H2-receptor antagonist effective at low dosage levels, is regarded as of particular benefit in the
treatment of these disorders.
Histamine H2-receptor antagonists for use in compositions of the invention include cimetidine, ranitidine and famotidine, preferably cimetidine and ranitidine, and especially
cimeditine. pKa values for known histamine H2-receptor antagonists are readily available from pharmacological publications.
Similarly, the above-mentioned parameters for a suitable buffering component are readily available to those skilled in the art. Suitable buffering agents for use in
compositions of the invention include aluminium hydroxide, magnesium hydroxide, aluminium hydroxide-magnesium carbonate co-dried gel, magnesium carbonate, magnesium oxide,
magnesium aluminium silicate, magnesium trisilicate, sodium bicarbonate, calcium carbonate, bismuth carbonate, alkali metal salts of citric, tartaric, benzoic, sorbic and
phosphoric acid, and combinations thereof. Further suitable antacids may be selected by pharmacokinetic analysis of the acid-secretion reducing capacity of a selected histamine H2-receptor antagonist using a
pharmacokinetic model based upon a modified, standard two-compartment model. With the introduction of further compartments to separately describe the stomach and the intestine, and with transport between the tissue
compartment, representing the parietal cell tissue receptor compartment, and the stomach lumen, the model may be used to describe pharmacokinetics for a selected histamine
H2-receptor antagonist. The model demonstrates the
reduction in local bioavailability of the histamine
H2-receptor antagonist at the parietal cell tissue receptor compartment as a function of gastric excretion and the increase in local bioavailability in the parietal cell tissue receptor compartment as a function of local, gastric absorption, and their dependence on gastric pH. Gastric pH levels are influenced by antacid. Thus, by inserting known values for equilibrium pH, acid neutralising capacity and gastric residence time, the suitability of any given antacid may be determined.
Conventional histamine H2-receptor antagonist therapies act systemically and drug is distributed to all parts of the body via the bloodstream. Hence, it will be appreciated that non-target body tissues are exposed to drug. An advantage of a locally targeted drug delivery system is that low doses may be used and thus pharmacologically relevant doses are not achieved in non-target tissues. Excretion of histamine H2-receptor antagonist into the stomach lumen from the parietal cell tissue receptor causes a reduction in local bioavailability of the antagonist whilst gastric absorption of histamine H2-receptor
antagonist into the parietal cell tissue receptor causes an increase in local bioavailability of the antagonist. An advantageous feature of the invention is the potential for using reduced dose levels of histamine H2-receptor
antagonist brought about by buffering the histamine
H2-receptor antagonist in the gastric environment,
effectively reducing antagonist excretion into the stomach lumen, increasing absorption from the stomach lumen, and increasing the residence time of the histamine H2-receptor antagonist in the gastric environment by forming a
bioadhesive complex.
The dose level of histamine H2-receptor antagonist may be selected according to the potency of the antagonist on a weight basis and according to the severity of the condition. For example where the histamine H2-receptor antagonist is cimetidine or ranitidine it may be present in an amount from about 1 mg to 800 mg per dosage form, typically from about 5 mg to 50 mg for example 5, 10, 15, 20 or 25 mg.
It will be further appreciated that treatment with the present compositions provides a more rapid onset of action which renders them particularly suitable for the treatment of acute gastritis.
A further aspect of the invention is that the amount of antacid present in any given composition is independent of the dose of histamine H2-receptor antagonist.
The bioadhesive material, for example sucralfate, may be present in an amount from about 100 mg to 1500 mg per dosage form, typically from about 800 mg to 1200 mg, for example 1000 mg. These dosage levels encompass compositions where sucralfate serves as the buffering component and which do not include a further buffering agent. Where a composition includes a bioadhesive material which has no buffering capacity or, in addition to sucralfate includes a further buffering agent, the level of buffer is optimally chosen to confer a pH substantially equal to that of the pKa of the histamine H2-receptor antagonist.
It is a feature of the buffering component that it serves a dual role. In one aspect, in the accepted mode of action of antacids, it brings about relief from the symptoms of excess stomach acidity by neutralisation. In a second aspect, and more importantly, it serves to act as an appropriate
buffered vehicle to enhance the absorption of the histamine H2-receptor antagonist. The dose of buffering agent may be selected to achieve both effects. A suitable dose range for magnesium hydroxide is from about 150 mg to 3000 mg, for example from about 300 mg to 1500 mg, such as from about 300 mg to 600 mg.
A suitable dose range for aluminium hydroxide is from about 180 mg to 3600 mg, for example from about 360 mg to 1800 mg, such as from 360 to 720 mg.
A suitable dose range for sodium bicarbonate is from about 400mg to 8,000mg for example from about 800 mg to 4000mg, such as from about 800mg to 1600mg.
Compositions for use in the present invention may also contain pharmaceutically acceptable carriers. Compositions may be formulated for oral administration in solid or liquid form, for example as tablets, capsules, powders, suspensions or dispersions. Compositions may thus be formulated by admixture with pharmaceutically acceptable vehicles
additionally containing, as desired, pharmaceutically acceptable adjuvants including inter alia thickeners, preservatives, and colouring and flavouring agents.
It will be appreciated that certain pharmaceutical
compositions for use in the present invention are novel and as such form a further aspect of the invention.
The following Examples illustrate the invention. The examples include sucralfate as the bioadhesive material but are not limited thereto. Any material having
bioadhesive properties, either a natural or synthetic material, may be incorporated into compositions for use in the invention.
Example 1
Entrapment of Cimetidine in Sucralfate Cimetidine solutions were made up at pH 2.5 at
concentrations in the range 0-200mg/ml. To 50ml of each cimetidine solution was added sucralfate (2g). 1 M HCl was added until a good paste was formed. Results mg/ml Cimetidine Nature of Paste Nature of supernatant
0 good clear
50 good clear
100 good clear
125 good clear
150 poor cloudy suspension
200 no paste cloudy suspension The results show that concentrations of cimetidine below 150 mg/ml are most favourable for entrapment. At concentrations above 150 mg/ml paste integrity is affected.
Example 2
Cimetidine Entrapment and Release from Sucralfate
The level of entrapment of cimetidine in sucralfate and the release of the entrapped cimetidine into solutiion as a function of time was determined. The levels of cimetidine studied were 0, 25, 50, 75, 100 and 125 mg/ml in a 50 ml volume.
Method A preweighed amount of cimetidine was added to 0.1 M
hydrochloric acid (30ml). The solution was mixed using a magnetic stirrer. A pH probe was inserted into the solution and 1M
hydrochloric acid was added until a clear solution (pH 2.5) was obtained. The volume was made up to 50ml. A 200 μl sample was removed. Sucralfate (2g ex Katsura) was added with stirring and allowed to disperse. 1 M HCl was added in 200 μl aliquots until paste formation occurred. Stirring was continued until the supernatant was clear. A 200 μl sample of
supernatant was removed.
The supernatant was poured off leaving the
cimetidine/sucralfate paste.
0.1M HCl (50ml) was added, the mixture swirled for 10 seconds and a 200 μl sample removed. A further 50ml sample of 0.1 M HCl was added. A 200 μl sample was removed. A third 50ml sample of 0.1M HCl (pH 1.5) was added. The resulting mixture was placed on an orbital shaker (GFL.3017) at 3/4 maximum speed.
200μl aliquots were removed after 1, 5, 15, 30 and 45 mins. and after 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours.
At the end of the experiment 5M HCl (5ml) was added to dissolve the sucralfate. This final solution was diluted and the total final level of sucralfate was determined
Each of the 200μl samples removed throughout the experment was assayed as follows: a 50μ sample was transferred to a vial and 1.95 ml. 0.1 M HCl was added. Further dilutions with distilled water were made as necessary. Optical density at 218mm was determined versus a distilled water blank.
At each cimetidine concentration, approximately 5% by weight of the available cimetidine is entrapped in sucralfate.
Visual observations indicated that the integrity of the paste was interfered with at cimetidine concentrations in excess of 75mg/ml. Agitation caused pieces of the paste mass to break off.
The release data indicates that release from sucralfate is a diffusional process.
Example 3
The Effect of pH on Cimetidine release from Sucralfate
Pastes
The rate of cimetidine release from sucralfate as a function of pH was determined at pH values 1.5, 3.0, 4.5, 6.0 and 7.5. The experiment was carried out using a cimetidine concentration of 50 mg/ml and 1g sucralfate. Theoretical pH Value
1. 5 3. 0 4 . 5 6. 0 7. 5
Total 1.079 1.082 1.117 1.105 1.045
Cimetidine (mg):
Experimental pH: 1.69 3.23 4.64 6.12 7.54
(initial)
Experimental pH: 3.21 3.17 4.57 6.18 7.66
(5hrs) The following table shows the release data as a function of % of total cimetidine entrapped within the sucralfate paste.
The results show the greatest release of cimetidine from the paste exposed to the pH of 1.5. As the pH increases, the amount of cimetidine released decreases up to pH 4.5. Above this pH, the level of release increases again.
Example 4
Powder Formulations The ingredients are dry blended under conditions of
controlled temperature and humidity using conventional equipment.
Example 5 - 6
Tablet Formulations
The active antacid ingredients are granulated or spray dried in a conventional manner. The granule, the histamine
H2-receptor antagonist and the bioadhesive material are blended along with conventional tabletting aids, fillers and palatability aids and the blend is tabletted on a
conventional machine. Example 7
Liquid Suspensions
Aluminium hydroxide and magnesium hydroxide are received as commercially available suspensions. These active
suspensions are added to a premix of thickeners. The resulting mixture is then blended with the histamine
H2-receptor antagonist, the bioadhesive material and
preservatives and flavours as appropriate.

Claims (13)

Claims
1. The use of an orally administrable pharmaceutical composition comprising a histamine H2-receptor antagonist and a bioadhesive material for the manufacture of a
medicament for the treatment of gastric disorders,
characterised in that the composition is formulated as an intimate mixture whereby the bioadhesive material and the histamine H2-receptor antagonist form, in-situ, a
bioadhesive complex, locally targeting the histamine H2- receptor antagonist to the stomach wall; and the composition is optimally buffered to confer a pH substantially equal to that of the pKa of the histamine H2-receptor antagonist, whereby local levels of the histamine H2-receptor antagonist at the parietal cell receptor are increased.
2. Use as claimed in claim 1 characterised in that the composition is optimally buffered with a buffering component which is an antacid having equilibrium pH, acid neutralising capacity and gastric residence time values which provide a pH profile with time conferring a local pH level
substantially equal to that of the pKa of the histamine H2-receptor antagonist.
3. Use as claimed in claim 1 or 2 for the treatment of gastric disorders in ulcer patients.
4. Use as claimed in claim 3 for the treatment of
patients who do not respond to conventional histamine H2-receptor antagonist therapy.
5. Use as claimed in claim 3 for the treatment of acid hypersecreting patients.
6. Use as claimed in claim 1 or 2 for the single-dose treatment of acute gastric disorders.
7. Use as claimed in any preceding claim whereby the histamine H2-receptor antagonist is cimetidine, ranitidine, or famotidine.
8. Use as claimed in claim 7 whereby the histamine H2-receptor antagonist is cimetidine.
9. Use as claimed in claim 8 whereby the dose level of cimetidine is from 1 to 800mg per dosage form.
10. Use as claimed in claim 9 whereby the dose level of cimetidine is from 5 to 50mg per dosage form.
11. Use as claimed in any preceding claim whereby the composition is buffered with aluminium hydroxide, magnesium hydroxide, aluminium hydroxide-magnesium carbonate co-dried gel, magnesium carbonate, magnesium oxide, magnesium
trisilicate, sodium bicarbonate, calcium carbonate, bismuth carbonate, magnesium aluminium silicate, alkali metal salts of citric, tartaric, benzoic, sorbic or phosphoric acid, or combinations of any of the aforementioned antacids.
12. A method of treatment of gastric disorders comprising orally administering to a sufferer an effective amount of a pharmaceutical composition comprising an intimate mixture of a histamine H2-receptor antagonist and a bioadhesive
material, and a buffering component wherein the equilibrium pH, the acid neutralising capacity and the gastric residence time values confer a pH level substantially equal to that of the pKa of the histamine H2-receρtor antagonist.
13. A pharmaceutical composition for use in the treatment of gastric disorders comprising an intimate mixture of a histamine H2-receptor antagonist and a bioadhesive material, and a buffering component wherein the equilibrium pH, the acid neutralising capacity and the gastric residence time values confer a pH level substantially equal to that of the pKa of the histamine H2-receptor antagonist.
AU89098/91A 1990-11-27 1991-11-21 Composition containing antihistamine H2 receptor antagonists and bioadhesive material Ceased AU659422B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9025710 1990-11-27
GB909025710A GB9025710D0 (en) 1990-11-27 1990-11-27 Novel treatment
PCT/GB1991/002063 WO1992009286A1 (en) 1990-11-27 1991-11-21 Composition containing antihistamine h2 receptor antagonists and bioadhesive material

Publications (2)

Publication Number Publication Date
AU8909891A AU8909891A (en) 1992-06-25
AU659422B2 true AU659422B2 (en) 1995-05-18

Family

ID=10686017

Family Applications (1)

Application Number Title Priority Date Filing Date
AU89098/91A Ceased AU659422B2 (en) 1990-11-27 1991-11-21 Composition containing antihistamine H2 receptor antagonists and bioadhesive material

Country Status (9)

Country Link
EP (1) EP0559812A1 (en)
JP (1) JPH06502855A (en)
AU (1) AU659422B2 (en)
CA (1) CA2096962A1 (en)
GB (1) GB9025710D0 (en)
IE (1) IE914091A1 (en)
PL (1) PL168421B1 (en)
WO (1) WO1992009286A1 (en)
ZA (1) ZA919290B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4139883A1 (en) * 1991-11-29 1993-06-03 Michael Prof Dr Dittgen Prodn. of bio-adhesive medicament, e.g. oral or vaginal tablet - comprises mixing drug with swellable, bio-adhesive polymer, dispersant and opt. binder
AU7322394A (en) * 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-sucralfate-antiflatulent combinations
WO1995010274A1 (en) * 1993-10-14 1995-04-20 F.H. Faulding & Co. Limited Aqueous pharmaceutical composition
GB9407235D0 (en) * 1994-04-12 1994-06-08 Glaxo Group Ltd Pharmaceutical compositions
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5985843A (en) * 1995-04-03 1999-11-16 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing sucralfate
EP0974361A4 (en) * 1996-02-08 2003-05-02 Chugai Pharmaceutical Co Ltd Method of using antacid agent and pharmaceutical preparation containing antacid agent
AU2957799A (en) * 1998-04-01 1999-10-18 Chugai Seiyaku Kabushiki Kaisha Preventives for alcoholic gastritis
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
WO2023218480A1 (en) * 2022-05-09 2023-11-16 Syri Research Private Limited Liquid oral formulation of famotidine or pharmaceutically acceptable salt thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3710462A1 (en) * 1987-03-30 1988-10-13 Heumann Pharma Gmbh & Co PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF DISEASES OF THE gastrointestinal tract
US4975281A (en) * 1989-01-30 1990-12-04 E. R. Squibb & Sons, Inc. Anti-ulcer composition
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production

Also Published As

Publication number Publication date
CA2096962A1 (en) 1992-05-28
IE914091A1 (en) 1992-06-03
ZA919290B (en) 1992-09-30
EP0559812A1 (en) 1993-09-15
GB9025710D0 (en) 1991-01-09
JPH06502855A (en) 1994-03-31
PL168421B1 (en) 1996-02-29
AU8909891A (en) 1992-06-25
WO1992009286A1 (en) 1992-06-11

Similar Documents

Publication Publication Date Title
US5629026A (en) Compositions containing histamine-H2-receptor antagonists at low dosage
CA2074215C (en) Improved oral dosing formulations of dideoxy purine nucleosides
HU211236A9 (en) Antacide compositions with prolonged gastric residence time
JPH05112445A (en) Transfer system that hastens initiation of action and increases latent characteristics
MXPA04000223A (en) Novel substituted benzimidazole dosage forms and method of using same.
AU659422B2 (en) Composition containing antihistamine H2 receptor antagonists and bioadhesive material
EP0533770A1 (en) Novel treatment
AU4082793A (en) Compositions based on histamine h2-receptor antagonists and cationic exchangers complexes
US4704278A (en) Fluidized magaldrate suspension
EP0492247A1 (en) Effervescent H2 blocker formulation
WO1996008238A1 (en) Use of paracellular absorption enhancers such as glucose for enhaincing the absorption of histamine h2-antagonists
EP0715520B1 (en) Use of a suspension based on sucralphate gel as antacid
AU677108B2 (en) Ranitidine and calcium carbonate pharmaceutical combination product
JPH10236959A (en) Composition containing antacid agent
WO1996002262A2 (en) Pharmaceutical compositions for the treatment of gastrointestinal distress comprising h2 receptor antagonists and antacids